Gene-editing stocks are exploding.
- CRISPR Therapeutics (CRSP) is up about $10 a share
- Editas Medicine (EDIT) is up about $4 a share
- Intellia Therapeutics (NTLA) is up about $40 a share
- Beam Therapeutics (BEAM) is up about $15 a share
All thanks to Intellia Therapeutics, Inc., a genome editing company that focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system.
Just this morning, the NTLA stock just exploded after releasing “interim data from the Phase 1 trial of its collaboration with Regeneron on an experimental therapy for transthyretin amyloidosis (ATTR) – a protein misfolding disorder,” as noted in a company press release.
“The data showed that for the six people that received a single 0.3 mg/kg dose of NTLA-2001, there was an 87% mean reduction in serum TTR, while there was a maximum 96% serum TTR reduction following a month’s treatment,” the company added.
Helping, RBC analyst Luca Issi, as quoted by Tip Ranks, says the data is a “major de-risking event for the platform,” and sees the shares surging by 35-45% on the news. Other names in the gene-editing space – BEAM, EDIT, CRSP – should also experience an uptick with the analyst also expecting to see retail money back in the mix.
This could be game changing news for patients and physicians.
The post Gene Editing Stocks Exploding on Impressive Intellia News appeared first on Morningology.
